FindTrial
Sign In

Tozinameran

BIOLOGICAL6 trials

Sponsors

The University of Hong Kong, Murdoch Childrens Research Institute, Mahidol University, Hannover Medical School, Fred Hutchinson Cancer Center

Conditions

Bullous DermatosesCOVID-19COVID-19 VaccinesCovid19Hematopoietic and Lymphatic System NeoplasmImmunization; InfectionMaternal Vaccine ExposurePsoriasis

Phase 2

Covid-19 Vaccination in Adolescents and Children
NCT04800133
The University of Hong KongCovid19
Start: 2021-05-08End: 2025-03-31Updated: 2024-01-16
Self-Amplifying mRNA COVID-19 Vaccine (LUNAR-COV19) Versus Comirnaty Vaccine in Adult Hematopoietic Cell Transplant Patients
Not yet recruitingNCT07390968
Fred Hutchinson Cancer CenterHematopoietic and Lymphatic System Neoplasm
Start: 2026-12-01End: 2029-01-01Target: 56Updated: 2026-09-17

Phase 3

COVID-19 Fourth Dose Study in Australia
WithdrawnNCT05543356
Murdoch Childrens Research InstituteCOVID-19
Start: 2022-05-02End: 2022-11-30Updated: 2024-03-15

Phase 4

Investigating COVID-19 Vaccine Immunity in Children in the Melbourne Infant Study of BCG for Allergy and Infection Reduction
CompletedNCT05168709
Murdoch Childrens Research InstituteCOVID-19, Immunization; Infection, Vaccine Reaction
Start: 2022-01-20End: 2022-09-29Updated: 2023-02-09
Intradermal Tozinameran for Patients With Immune-mediated Dermatologic Diseases
CompletedNCT05406908
Mahidol UniversityBullous Dermatoses, COVID-19 Vaccines, Psoriasis
Start: 2022-06-15End: 2023-05-01Updated: 2024-03-25

Unknown Phase

Priming of the NEonatal Immune System by Transfer of Maternal Immunity
NCT05429047
Hannover Medical SchoolCOVID-19, Maternal Vaccine Exposure, Respiratory Infections in Children
Start: 2022-06-07End: 2023-12-01Target: 560Updated: 2022-07-07

Related Papers

The immunogenicity, reactogenicity, and safety of a bivalent mRNA or protein COVID-19 vaccine given as a fourth dose.
2025-02-182 citations
Superior antibody and membrane protein-specific T-cell responses to CoronaVac by intradermal versus intramuscular routes in adolescents.
2023-12-122 citations
Immunogenicity against wild-type and Omicron SARS-CoV-2 after a third dose of inactivated COVID-19 vaccine in healthy adolescents
Frontiers in Immunology2023-03-069 citations
Antibody and T cell responses against wild-type and Omicron SARS-CoV-2 after third-dose BNT162b2 in adolescents.
2022-12-1410 citations
Safety and immunogenicity of 3 doses of BNT162b2 and CoronaVac in children and adults with inborn errors of immunity
Frontiers in Immunology2022-09-2017 citations
Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents
Nature Communications2022-06-2866 citations
Bacillus Calmette‐Guérin Scar erythema in a 14‐year‐old girl post‐BNT162b2 vaccination
Pediatrics International2022-01-013 citations